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Severe inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis, are caused
by mutations in genes preferentially expressed in photoreceptors. While adeno-associated virus (AAV)-medi-
ated gene transfer can correct retinal pigment epithelium (RPE) defects in animal models, approaches for the
correction of photoreceptor-specific diseases are less efficient. We evaluated the ability of novel AAV serotypes
(AAV2/7, AAV2/8, AAV2/9, AAV2rh.43, AAV2rh.64R1, and AAV2hu.29R) in combination with constitutive or
photoreceptor-specific promoters to improve photoreceptor transduction, a limiting step in photoreceptor
rescue. Based on a qualitative analysis, all AAV serotypes tested efficiently transduce the RPE as well as rod
and cone photoreceptors after subretinal administration in mice. Interestingly, AAV2/9 efficiently transduces
Mu¨ller cells. To compare photoreceptor transduction from different AAVs and promoters in both a qualitative
and quantitative manner, we designed a strategy based on the use of a bicistronic construct expressing both
enhanced green fluorescent protein and luciferase. We found that AAV2/8 and AAV2/7 mediate six- to eightfold
higher levels of in vivo photoreceptor transduction than AAV2/5, considered so far the most efficient AAV
serotype for photoreceptor targeting. In addition, following subretinal administration of AAV, the rhodopsin
promoter allows significantly higher levels of photoreceptor expression than the other ubiquitous or photore-
ceptor-specific promoters tested. Finally, we show that AAV2/7, AAV2/8, and AAV2/9 outperform AAV2/5
following ex vivo transduction of retinal progenitor cells differentiated into photoreceptors. We conclude that
AAV2/7 or AAV2/8 and the rhodopsin promoter provide the highest levels of photoreceptor transduction both
in and ex vivo and that this may overcome the limitation to therapeutic success observed so far in models of
inherited severe photoreceptor diseases.
Inherited retinal diseases, such as retinitis pigmentosa (RP)
and Leber congenital amaurosis (LCA), are characterized by
progressive impairment of visual function associated with pho-
toreceptor loss (14, 21, 34). RP and LCA are monogenic,
highly genetically heterogeneous diseases due to mutations in
genes primarily expressed in the retinal pigment epithelium
(RPE) or in photoreceptors (14, 21). In fact, the majority of
genes associated with retinal inherited diseases are photore-
ceptor specific. Gene therapy holds great potential for the
treatment of inherited retinal diseases for which there cur-
rently is no cure. Efficient retinal gene transfer has been
achieved with several viral vectors, including those derived
from adenovirus, retrovirus, herpesvirus, and adeno-associated
virus (AAV) (15). Among these, AAV vectors appear partic-
ularly amenable to retinal gene transfer, because they are non-
pathogenic and they efficiently transduce nondividing cells po-
tentially for the life of the experimental animal following a
single administration (5, 9). Since the generation of the first
AAV vector (30, 53) (AAV2/2, in which the first number de-
fines the vector genome and the second the capsid), dozens of
AAV variants have been isolated, and some of them have been
converted into gene delivery vehicles (11, 12, 23–25, 45). AAV
serotypes differ in their compositions of the capsid surface
proteins, which affect their tropism and transduction. We and
others have demonstrated that it is possible to tailor somatic
transgene expression on distinct retinal cell types in the adult
and fetal retina by exchanging the AAV capsids among the
various AAV serotypes and that this may impact the therapeu-
tic outcome in animal models of retinal diseases (7, 44, 51, 57).
While AAVs are suitable for gene transfer to different retinal
cell types in vivo, their ability to transduce retinal stem cells
and their derivatives has not been characterized yet. This lim-
itation hampers the possibility of genetically modifying retinal
stem cells derived from the adult eye (54), which can be used
as tools for cell therapy of retinal degenerations.
Among the various AAV vectors tested so far in the retina,
AAV2/1 and AAV2/4 are considered ideal vectors for RPE
gene transfer (7, 51, 56, 57), and AAV2/5 is considered ideal
for photoreceptor transduction (7, 37). AAV2/2, AAV2/1, and
AAV2/4 have been used successfully to treat RPE-specific
genetic defects, including mucopolysaccharidoses (29, 31), oc-
ular albinism (52), and RP and LCA due to MERTK and
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RPE65 gene deficiencies, respectively (1, 2, 16, 32a, 35, 39, 41,
50). In particular, the most remarkable results using AAV-
mediated gene transfer have been obtained in the Briard dog
bearing homozygous mutations in the RPE65 gene, a model of
LCA (1, 2, 32a,35, 39). RPE65 gene transfer resulted in stable
restoration of visual function, regardless of the AAV vector
used, suggesting that, at least in animal models, treatment of
RPE-specific diseases does not depend on the capsid used.
Various centers are testing the toxicity and tolerability of
AAV2/2 vectors in the retinas of patients with RPE65 muta-
tions (10). Gene transfer approaches for photoreceptor-spe-
cific diseases have been successful in rare cases (38, 43, 59),
probably due to limitations of the vector system, the nature of
photoreceptor-specific retinal degenerations, and constraints
in photoreceptor accessibility to vectors. The ability of AAV
vectors to transduce RPE more efficiently than photoreceptors
may be related to the simple monolayer organization of the
RPE as opposed to the photoreceptors that are higher in
number and architectonically organized in rows (13), which
may represent a physical barrier to their transduction. A para-
digmatic example of the challenge represented by the rescue of
photoreceptor diseases is the attempt to use AAV2/2 vectors to
treat mice carrying loss-of-function mutations in the PDE6B
gene (rd1 mice) (33). In this case, evidence of prolonged and
sustained morphological and functional photoreceptor rescue
is lacking, probably due to the combination of low levels of
photoreceptor transduction by AAV2/2 vectors and the sever-
ity of the rd1 degeneration (33). Similarly, in the rds model of
photoreceptor disease due to peripherin deficiency, AAV2/2-
mediated gene transfer resulted in short-lived rescue of pho-
toreceptor survival (4, 47, 49). The mechanism of photorecep-
tor loss suggests that gene transfer efficiency may be a limiting
factor for photoreceptor rescue. RP initially affects the periph-
eral retina, resulting in the degeneration of rods, while cones
and central vision are preserved at this stage (21). With the
progression of the disease, the cones also degenerate (rod-
cone degeneration), suggesting a non-cell-autonomous mech-
anism of cell death. Nonautonomous patterns of degeneration
similarly are observed in those inherited retinal diseases pri-
marily affecting cones, such as cone-rod dystrophies, suggest-
ing a general mechanism of degeneration in inherited retinal
diseases (28). Therefore, widespread photoreceptor transduc-
tion is desirable to prevent detrimental effects from nontrans-
duced photoreceptors.
We evaluated the efficiency of photoreceptor gene transfer
mediated by six novel AAV serotypes and isolates (we refer to
them as novel because they have not been previously tested in
the retina) in combination with constitutive and photorecep-
tor-specific promoter elements. We determined their onset,
tropism, distribution, and levels of transgene expression and
compared them to those of AAV2/5, so far the most efficient
vehicle system for photoreceptor targeting (7, 37). The impact
of novel AAV capsids and promoter elements on photorecep-
tor gene transfer was determined with a strategy that allows
precise quantification of levels of transgene expression in pho-
toreceptors. We found that the combination of capsids from
AAV7 or AAV8 combined with the 800-bp proximal fragment
of the rhodopsin (RHO) promoter results in the highest levels
of photoreceptor transduction.
MATERIALS AND METHODS
Generation of the plasmid constructs. For the production of AAV encoding
enhanced green fluorescent protein (EGFP) with different promoters, pAAV2.1-
CMV-EGFP (6), pAAV2.1-CBA-EGFP, pAAV2.1-RHO-EGFP, and pAAV2.1-
RHOK-EGFP plasmids were used. pAAV2.1-RHO-EGFP and pAAV2.1-
RHOK-EGFP were obtained by exchanging the cytomegalovirus (CMV)
promoter of pAAV2.1-CMV-EGFP with the RHO or RHO kinase (RHOK)
promoter sequences. The RHO (800 to 6; GenBank accession number
U16824) and RHOK (112 to 86 [58]) promoters were amplified from human
genomic DNA. PCR was performed to insert the NheI and NotI sites at the 5
and 3 ends, respectively. For the RHO promoter, we used the following prim-
ers: NheI-RHOFor, 5-AATTATGCTAGCAGATCTTCCCCACCTAGC-3; and
RHORev-NotI, 5-ATTAATGCGGCCGCGGATGACTCTGGGTTCTG-3. For
RHOK we used the following primers: NheI-0.11KbRHOKFor, 5-GCTAGCGG
GCCCCAGAAGCCTGG-3; and 0.11KbRHOKRev-NotI, 5-GCGGCCGCCCC
GGGGCTGACACAGC-3. The PCR products then were digested with NheI and
NotI and were cloned into pAAV2.1-CMV-EGFP after removing the CMV pro-
moter. The chicken -actin (CBA) promoter was amplified from the pCAGGS
plasmid (a kind gift of M. Studer, TIGEM, Naples, Italy) by PCR to insert the
NcoI and PstI sites at the 5 and 3 ends, respectively. The PCR product then was
cloned into pAAV2.1-CMV-EGFP (with NcoI-PstI digestion) downstream of the
CMV enhancer. To produce the pAAV2.1-CMV-, RHO-, RHOK-, and CBA-
NLSEGFP-IRES-LUCIFERASE plasmids, we initially produced the pNL
SEGFP-IRES-LUCIFERASE plasmid. The coding sequence for firefly lucifer-
ase (1.7 kb) was obtained from pZac2.1-CMV-LUCIFERASE plasmid (6) by
cutting it with NheI-XbaI restriction enzymes and inserting it into XbaI-digested
pIRES plasmid (Clonthech) to produce the pIRES-LUCIFERASE plasmid. The
sequence of an expression cassette containing the coding sequence for the EGFP
with a nuclear localization signal (NLS) (designated NLSEFGP) was amplified
from pAAV2.1-CMV-EGFP plasmid with the following primers: forward, 5-G
CGGCCGCCATGCCTAAGAAGAAGAGAAAGGTGGAGGTGAGCAAG
GGCGAGGAGCTG-3; and reverse, 5-TTAACTTGTACAGCTCGTCCATG
CC-3. The forward primer contains the NotI restriction site and the translational
start site (ATG) followed by the nuclear localization sequence of the simian virus 40
(SV40) large T antigen (PKKKRKVE) (17). The PCR product was EcoRI digested
from pCR2.1-TOPO plasmid (Invitrogen) and inserted in the pIRES-LUCIFER
ASE plasmid to produce the pNLSEGFP-IRES-LUCIFERASE plasmid. The NL
SEGFP-IRES-LUCIFERASE sequence then was removed (with NotI-SalI) from
pNLSEGFP-IRES-LUCIFERASE and was inserted into pAAV2.1-CMV-EGFP
cut with NotI and BglII to produce pAAV2.1-CMV-NLSEGFP-IRES-LUCIFER
ASE. The pAAV2.1-RHO-NLSEGFP-IRES-LUCIFERASE, pAAV2.1-RHOK-
NLSEGFP-IRES-LUCIFERASE, and pAAV2.1-CBA-NLSEGFP-IRES-LUCIF
ERASE plasmids were obtained by exchanging the CMV promoter of pAAV2.1-
CMV-NLSEGFP-IRES-LUCIFERASE with the RHO, RHOK, and CBA pro-
moter sequences obtained from pAAV2.1-RHO-EGFP, pAAV2.1-RHOK-EGFP,
and pAAV2.1-CBA-EGFP plasmids, respectively, by NheI-NotI digestion. The
SV40 intron present only in the pAAV2.1-CMV-NLSEGFP-IRES-LUCIFER
ASE and pAAV2.1-CBA-NLSEGFP-IRES-LUCIFERASE plasmids was elimi-
nated by PstI and NotI digestion. The pAAV2.1-CMV-LacZ plasmid was previously
described (6), while pAAV2.1-RHOK-LacZ was produced by exchanging the CMV
promoter with RHOK (using NheI-NotI digestion). The AAV2/rh.64R1 capsid
sequence was based on AAV isolate rh.64 (23) and was optimized for production by
an R697W mutation in VP1 (L. H. Vanderberghe and J. M. Wilson, unpublished
data).
AAV vector production and subretinal administration. AAV vectors were
produced by the TIGEM AAV Vector Core using pAAV2.1-CMV-, -CBA-
EGFP, -RHO-EGFP, -RHOK-EGFP, pAAV2.1-CMV-, RHO-, RHOK-, CBA-
NLSEGFP-IRES-LUCIFERASE, pAAV2.1-CMV, and RHOK-LacZ plasmids.
Recombinant AAV2/5, AAV2/7, AAV2/8, AAV2/9, AAV2/rh.64R1, AAV2/
rh.43, and AAV2/rh.29R viruses were produced by triple transfection of 293 cells
followed by CsCl2 purification (6). For each viral preparation, physical titers (in
genome copies [GC]/milliliter) were determined by both PCR quantification
using TaqMan (Perkin-Elmer, Life and Analytical Sciences, Inc.) and dot blot
analysis (20).
All procedures on animals were performed in accordance with institutional
guidelines of the ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research. Four-week-old male C57BL/6 mice (Harlan) were used. Before
vector administration, mice were anesthetized with an intraperitoneal injection
of avertin (1.25% [wt/vol] 2,2,2-tribromoethanol and 2.5% [vol/vol] 2-methyl-2-
butanol [Sigma-Aldrich]) at 2 ml/100 g of body weight (42). Subretinal vector
administrations were performed as described previously (36).
VOL. 81, 2007 NOVEL AAV SEROTYPES TRANSDUCE PHOTORECEPTORS 11373
 at Ist. G
em
etica e biofisica on January 7, 2008 
jvi.asm.org
D
ow
nloaded from
 
Fundus photography. Fundus photographs of mice were taken with a Topcon
TRC-50IX retinal camera connected to a charge-coupled-device Nikon D1H
digital camera (Topcon Medical System) after anesthetizing the animals, dilating
their pupils, and fixing them on a stereotaxic table.
Histological analysis. Mice were sacrificed, and their eyeballs were harvested
and fixed overnight by immersion in 4% paraformaldehyde. The eyeballs were
cut so that the lens and vitreous could be removed, leaving the eyecup. Mice
eyecups were infiltrated with 30% sucrose for cryopreservation and were em-
bedded in tissue-freezing medium (O.C.T. matrix; Kaltek). For each eye, 150 to
200 serial sections (10 m thick) were cut along the horizontal meridian, and the
sections were progressively distributed on 10 slides so that each slide contained
15 to 20 sections representative of the whole eye at different levels. The sections
were stained with 4,6-diamidino-2-phenylindole (DAPI) (Vectashield; Vector
Laboratories, Inc.), and retinal histology images were obtained with an Axiocam
(Carl Zeiss) with 20 magnification.
PNA immunolabeling on retinal sections and cone counting. Sections were
rinsed in phosphate-buffered saline (PBS) and incubated for 1 h in 10% fetal
bovine serum (FBS) in PBT (0.1% Triton 100, 0.1% bovine serum albumin in
PBS). The incubation with biotinylated peanut agglutinin (PNA) (400 g/ml in
PBT; Vector Laboratories) or anti-glutamine synthetase (GS6) (1:500 in PBT;
Chemicon) was performed overnight at 4°C. The sections then were washed
three times with PBS and incubated with Alexa Fluor 568-coupled streptavidin
(1:250 in PBT; Molecular Probes) or Alexa Fluor 568-coupled anti-rabbit anti-
body (1:500 in PBT; Molecular Probes) for 1 h at room temperature (RT). After
a final wash, sections were mounted with DAPI (Vectashield), and images were
obtained with a confocal microscope (Leica DMIRE2 and Leica confocal soft-
ware) with 63 magnification. To quantify the transduced cones, we counted the
number of EGFP-positive cones, defined by their typical morphology and by the
colinearity of PNA-lectin labeling with EGFP expression, in a 40 magnification
area of at least three different sections for each eye (n  3 eyes/group). The
number of EGFP-positive cones was divided by the total number of cones
present in the same 40 magnification area to obtain the percentage of trans-
duced cones. The percentage of transduced cones from each serotype then was
averaged, and standard errors were calculated.
Luciferase and -Gal assays. Harvesting of retinas was performed as de-
scribed previously (8). Luciferase activity and -galactosidase (-Gal) levels were
measured in retina lysates using the luciferase reporter gene assay (Roche) and
-Gal enzyme-linked immunosorbent assay (Roche) according to the manufac-
turer’s instructions.
Retinal stem cell culture and infection. Retinal stem cells were isolated from
adult rats and were cultured as described previously (46). Apoptosis in retinal
degeneration involves cross talk between apoptosis-inducing factor and
caspase-12 and is blocked by calpain inhibitors (46). Retinal neurospheres were
allowed to differentiate with 1% FBS on a substrate of laminin (2.5 g/ml) and
poly-D-lysine (20 g/ml) for 9 days. Cells then were infected with AAV2/5-CMV-
EGFP, AAV2/7-CMV-EGFP, AAV2/8-CMV-EGFP, and AAV2/9-CMV-EGFP
(1  105 GC of each vector/cell). Three days after infection, cells were fixed and
incubated for 1 h with 10% FBS in PBS. The incubation with anti-RHO antibody
1D4 (1:400) was performed for 90 min at RT. After extensive washes with PBS,
cells were incubated with Alexa Fluor 568 anti-mouse secondary antibody (1:
1,000 in PBS; Molecular Probes) for 1 h at RT. After a final wash, slides were
coverslipped with Vectashield and photographed using an Axioplan microscope
(Zeiss) with 63 magnification.
RESULTS AND DISCUSSION
Onset of transgene expression and tropism of novel AAV
serotypes in the murine retina. To evaluate the tropism of
novel AAV serotypes following subretinal delivery to the adult
murine retina and to determine if one is selective for photo-
receptors, we generated AAV2/7 (25), AAV2/8 (25), AAV2/9
(23), AAV2/rh.43 (23), AAV2/rh.64R1 (23; Vanderberghe and
Wilson, unpublished), AAV2/hu.29R (55), and AAV2/5 (11)
vectors harboring the AAV2 vector genome, coding for EGFP,
under the control of the ubiquitous CMV promoter. The novel
serotypes were selected based on their ability to transduce
various tissues (AAV2/7, AAV2/8, and AAV2/9 [25]) or the
adult murine retina in a pilot experiment (L. H. Vandenberghe
and J. M. Wilson, personal communication) and on their phy-
logenetic origins (23). Regarding the latter aspect, AAV2/7
belongs to clade D; AAV2/9 belongs to clade F; AAV2/8,
AAV2/rh.43, and AAV2/rh.64R1 belong to clade E; and
AAV2/hu.29R belongs to clade B (AAV2/5 is divergent from
any other AAV isolated so far) (23). One eye of 4-week-old
C57BL/6 mice (n  4 animals/group) was administered 6.8 
109 GC of AAV2/5, and the same dose of each of the novel
AAV serotypes was separately administered in the controlat-
eral eye. The onset of EGFP expression was assessed by indi-
rect ophtalmoscopy and was evident at 5 days postinjection in
the retinas that received AAV2/5, AAV2/7, and AAV2/8, at 7
days in those that received AAV2/rh.43, AAV2/rh.64R1, and
AAV2/hu.29R, and at 11 days in those that received AAV2/9
(Fig. 1A, second and fourth rows). Four weeks after injection,
retinal sections were analyzed by direct fluorescence evalua-
tion to assess AAV vector tropism. As shown in the first and
third rows of Fig. 1A, all vectors efficiently transduce photo-
receptors and the RPE with distribution and expression levels
apparently similar to those of AAV2/5. In addition, the retinas
that received AAV2/8 and, in particular, AAV2/9 showed
EGFP expression in Mu¨ller cells, as confirmed by colocaliza-
tion with GS6, a known marker of Mu¨ller cells (18) (Fig. 1A,
first row, and B). The same levels of EGFP expression and
transduction patterns were observed in retinal sections 3
months after AAV administration. To assess the ability of
AAV serotypes to transduce cones, we stained the cone outer
segments with PNA-lectin, given their low density in the outer
nuclear layer. Confocal immunofluorescence analysis revealed
that cones, in addition to rods, were efficiently transduced by
all AAV vectors tested (Fig. 1C). To quantify the number of
cones transduced, we calculated the percentage of all individ-
ual cone sheaths expressing EGFP on 40 magnification op-
tical fields (n  3 eyes/group). AAV2/8 (75%  6.7% cones)
and AAV2/9 (75%  7.7% cones) transduced the highest
number of cones, while AAV2/rh.64R1 (28%  5.1% cones),
AAV2/rh.43 (23%  4.9% cones), and AAV2/rh.29R (33% 
7.0% cones) transduced cones to levels similar to that of
AAV2/5 (35%  6.7% cones). To assess potential detrimental
effects to retinal function due to the subretinal injection pro-
cedure or to vector administration, electroretinographic anal-
yses were performed. No significant changes in scotopic and
photopic electroretinographic a- and b-wave amplitudes were
observed between uninjected and AAV-injected eyes (data not
shown). In addition, hematoxylin and eosin staining revealed
no signs of inflammatory infiltration in the treated eyes (data
not shown). We conclude that all novel AAV serotypes ana-
lyzed transduce various retinal cell types, including photore-
ceptors, and show early onset of transgene expression; none of
the AAV serotypes tested transduces exclusively or predomi-
nantly photoreceptors.
Ubiquitous and photoreceptor-specific promoters in the ret-
ina. Various promoter elements have been tested so far and
are routinely used to express exogenous genes in the retina
following somatic gene transfer (5, 19). These include the
photoreceptor-specific proximal portion of the human RHO
promoter (22, 26) and the CMV (27) and CBA (48) promoters.
In order to evaluate their activity side by side, we generated
AAV2/5 vectors expressing EGFP from each of them. We
additionally tested AAV2/5 vectors encoding EGFP from the
proximal region of the human RHOK (116 to 86 [58])
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FIG. 1. Subretinal administration of novel AAV serotypes expressing EGFP in adult C57BL/6 mice. (A) The first and third rows depict
fluorescence microscopy evaluations of EGFP expression 4 weeks after subretinal injection with AAV2/5-CMV-EGFP, AAV2/7-CMV-EGFP,
AAV2/8-CMV-EGFP, AAV2/9-CMV-EGFP, AAV2/rh.64R1-CMV-EGFP, AAV2/rh.43-CMV-EGFP, and AAV2/rh.29R-CMV-EGFP. Abbrevi-
ations: ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer. White arrows, Mu¨ller cell nuclei; red arrows, Mu¨ller cell
endfoot membranes. The second and fourth rows depict in vivo imaging of EGFP fluorescence in mouse retinas 5 days after subretinal injections
of AAV2/5-CMV-EGFP, AAV2/7-CMV-EGFP, and AAV2/8-CMV-EGFP, 11 days after injection of AAV2/9-CMV-EGFP, and 7 days after
injection of AAV2/rh.64R1-CMV-EGFP, AAV2/rh.43-CMV-EGFP, and AAV2/rh.29R-CMV-EGFP. Fundus photographs show punctate EGFP
fluorescence diffusing from the site of the subretinal injection to 30 to 40% of the treated retina. (B) Mu¨ller cell transduction by AAV2/9 vectors
expressing EGFP from the CMV promoter. Staining with anti-GS6 antibody (GS6; red label) on retinal sections of animals injected with
AAV2/9-CMV-EGFP is shown. Colocalization of EGFP expression and GS6 staining is indicated by the arrows (MERGE). Microscope
magnification, 20. (C) Cone transduction from novel AAV serotypes expressing EGFP from the CMV promoter. Staining with PNA-lectin (red
label) on retinal sections of animals injected with AAV2/8-CMV-EGFP or AAV2/rh.43-CMV-EGFP is shown. Colocalization of EGFP expression
and PNA staining is indicated by the arrows. Confocal microscope magnification, 63.
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promoter, responsible for photoreceptor-restricted expression
in transgenic animals (58). The AAV2/5 vectors with the var-
ious promoters were injected subretinally (6.8  109 GC of
each vector/eye) into 4-week-old C57BL/6 mice (n  4 ani-
mals/group). To assess the onset of EGFP expression, we per-
formed ophthalmoscopic examinations every week after vector
administration. The onset of EGFP expression appeared at 5
and 12 days after vector administration when the CMV and the
CBA promoters, respectively, were used, while EGFP expres-
sion under the control of the RHO and the RHOK promoters
was evident 3 to 4 weeks after vector delivery. The differences
in the onset of gene expression between ubiquitous and pho-
toreceptor-specific promoters may be due to the fact that
EGFP expression in the RPE is more easily detectable by
ophthalmoscopic examination than EGFP expression re-
stricted to photoreceptors. One month after vector adminis-
tration, the eyes were enucleated and histological analysis of
EGFP expression was performed (Fig. 2, top row). Similar to
what was reported in previous studies, EGFP expression from
AAV2/5 vectors harboring the CMV or the CBA promoter is
localized to both RPE and photoreceptors and, in some cells,
to the inner nuclear layer, whereas the RHO and the RHOK
promoters restrict transgene expression to photoreceptors.
The fluorescence microscope analysis shows that the most ro-
bust expression levels among the promoters tested in photore-
ceptors seem to be provided by the RHO promoter element,
while the lowest levels of expression seem to be provided by
the RHOK promoter element (Fig. 2, top row). The same
levels of EGFP expression and transduction patterns were
observed in retinal sections 3 months after AAV administra-
tion. With a method similar to that used for the comparison
between capsids, we analyzed cone transduction levels by the
various promoters using PNA-lectin staining. Confocal micros-
copy analysis demonstrated that both ubiquitous and photore-
ceptor-specific promoters drive efficient EGFP expression in
cone photoreceptors in the context of vectors with AAV5 cap-
sids (Fig. 2, bottom row). This result suggests that AAV2/5
efficiently infects cones and that both the RHO and RHOK
regulatory elements allow expression in both rods and cones,
as previously shown (26, 40). Among the promoters tested (n
3 eyes/group), the most efficient promoter for transgene ex-
pression in cones is the CBA promoter (58.4%  2.4% cones),
followed by the RHOK (47%  6.7% cones), RHO (44.6% 
3.8% cones), and CMV (36.1%  6.2% cones) promoters as
assessed by counting the number of double-stained cones
(PNA and EGFP)/microscopic field in the area of maximal
transduction.
Quantification of photoreceptor transduction with novel
AAV serotypes and promoters. To measure transgene expres-
sion levels in photoreceptors following subretinal delivery of
novel AAV serotypes and promoters, we generated an expres-
sion cassette containing the coding sequence for the EGFP
with an NLS (designated NLSEFGP), followed by the internal
ribosomal entry site sequence and the coding sequence for the
firefly luciferase (Fig. 3). The NLSEGFP transgene produces
lower, nonsaturating levels of green fluorescence than EGFP,
and it is localized mainly but not exclusively to the nucleus.
Therefore, NLSEGFP provides qualitative information on cel-
lular targets, while luminometric measurements of luciferase
levels provide quantitative information. To compare the im-
pact of different capsids on photoreceptor-specific transduc-
tion levels, we cloned the RHO promoter element (which
restricts expression to photoreceptors) upstream of the bicis-
tronic construct; thus, the measure of luminescence due to
luciferase expression provides an estimate of levels of photo-
receptor-specific transduction. We subretinally coinjected
FIG. 2. Subretinal injections of AAV2/5-EGFP vectors with various promoters into adult C57BL/6 mice. The images in the top row depict
fluorescence microscopy evaluation of EGFP expression 4 weeks after subretinal injections of AAV2/5 encoding EGFP from the CMV, CBA,
RHO, and RHOK promoters. Abbreviations: ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer. The images in the
bottom row show staining with PNA-lectin (red label) on retinal sections of animals injected with AAV2/5-CMV-EGFP, AAV2/5-CBA-EGFP,
AAV2/5-RHO-EGFP, and AAV2/5-RHOK-EGFP. Colocalization of EGFP expression and PNA staining is indicated by the arrows. Confocal
microscope magnification, 63. The selected field shows the colocalization of cone sheathes (PNA, red label) and EGFP expression (green label)
at increased magnification. The magnified portion depicts the onset of gene expression as assessed by indirect ophthalmoscopy.
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adult C57BL/6 mice (4 weeks old) with 3  109 GC of each of
the various vectors shown in Fig. 3A, together with 6.9  108
GC of an AAV2/5 vector encoding Escherichia coli -Gal un-
der the control of the CMV promoter (AAV2/5-CMV-LacZ).
Relating luciferase levels to those of -Gal allowed us to min-
imize the potential variability in the dose of the vector deliv-
ered following subretinal administration. After 1 month, eyes
were harvested and the retinas were either processed for his-
tological analysis or lysed to measure both luciferase activity
and -Gal levels. As shown in Fig. 4A, the ratio between
luciferase and -Gal was higher for the eyes treated with
AAV2/7, AAV2/8, and AAV2/9 (437  87, 316  86, and
181  44 relative light units [RLU], respectively) than for
those treated with AAV2/5 (51 12 RLU), while for serotypes
AAV2/rh.64R1, AAV2/rh.43, and AAV2/hu.29R the values
were similar to those for AAV2/5 or were lower (29  4, 6 
1, and 49  12 RLU, respectively). To rule out the possibility
that the low values obtained with the AAV2/5 vector were due
to competition with the same serotype used for normalization
(although the doses of AAV2/5-CMV-LacZ administered were
six times lower than those of the bicistronic vectors), we re-
peated the experiment using AAV2/1-CMV-LacZ as a normal-
izing vector. The results were comparable between the two sets
of experiments (data not shown). We then analyzed the ability
of the novel AAV serotypes to transduce in vitro-differentiated
photoreceptors from retinal stem cells. Based on the in vivo
quantitative analysis, we chose to compare transduction effi-
ciencies of AAV2/5, AAV2/7, AAV2/8, and AAV2/9, which
showed the highest levels of photoreceptor transduction. Ret-
inal stem cells were isolated from the adult ciliary margin and
were grown for 6 days as neurospheres. Neurospheres then
were allowed to differentiate to photoreceptors (RHO-positive
cells) for 9 days and were treated with the various AAV sero-
types (1  105 GC/cell). Three days later the percentage of
transduced photoreceptors was calculated by counting cells
coexpressing EGFP and RHO (Fig. 5B). While AAV2/5 was
not able to transduce in vitro-differentiated photoreceptors, we
found that AAV2/7, AAV2/8, and AAV2/9 are the best sero-
types for in vitro genetic modification of retinal stem cells,
allowing expression of transgenes in more than 80% of RHO-
positive cells (Fig. 5A).
To identify the most efficient promoter for expression in
photoreceptors, retinas were transduced with vectors contain-
ing the AAV5 capsid and the bicistronic expression cassette
under the control of the CMV, CBA, RHO, or RHOK pro-
moter separately (Fig. 3B). The AAV2/5 vectors (1.9  109
GC/eye of each vector) were coinjected subretinally into adult
C57BL/6 mice, with AAV2/1-CMV-LacZ being injected for
normalization. Whole retinas (including the inner nuclear
layer and sporadic RPE cells) were peeled 1 month after AAV
administration and were analyzed for luciferase and -Gal
activities. The highest ratio between luciferase and -Gal was
obtained using the RHO promoter (111  31.8 RLU), which
had ratios that were 10- to 13-fold higher than those obtained
using the ubiquitous CBA (11  2.8 RLU) and CMV (8.1 
2.1 RLU) promoters and nearly 24-fold higher than that ob-
tained using the RHOK promoter (4.6 1.1 RLU). In the case
of ubiquitous promoters, the values obtained are an overesti-
mation of photoreceptor transduction, as luciferase expression
is not restricted to photoreceptors in the samples analyzed,
although the majority of the retinal cells transduced by AAV2/
5-CMV-EGFP are photoreceptors (Fig. 2). In addition, the
majority of RPE cells are carefully removed from the retinal
samples when they are peeled from the eyecups. Therefore,
nonphotoreceptor cells likely minimally influence the quanti-
tative results. With a procedure similar to that used for capsid
comparisons, this experiment was repeated using an AAV2/1-
RHOK-LacZ vector for normalization to exclude the possibil-
ity that competition between CMV promoters could account
for the low levels of luciferase measured when AAV2/1-CMV-
LacZ was injected. The results were similar between the two
sets of experiments (data not shown).
In conclusion, our data demonstrate that the AAV serotypes
tested efficiently transduce photoreceptors and RPE following
subretinal delivery. Interestingly, AAV2/9 also transduces
Mu¨ller cells. AAV2/7, AAV2/8, and AAV2/9, as well as each of
the promoters tested, determine high levels of gene expression
in cone photoreceptors. We also show that AAV2/8 and
AAV2/7 mediate six- to eightfold greater transgene expression
levels in photoreceptors than AAV2/5, considered so far the
most efficient vector for photoreceptor gene transfer. AAV2/9
also was more effective than AAV2/5 but was less effective than
AAV2/7 and AAV2/8 at photoreceptor transduction. Interest-
ingly, the ability of the AAV serotypes to transduce photore-
ceptors is independent of their homology in the capsid amino
acid sequence. For instance, AAV8 and AAVrh.43 capsids are
very closely related, with only 2% divergence in their VP1
capsid sequences (23). Nevertheless, the photoreceptor trans-
duction efficiency in retinas injected with AAV2/8 was signifi-
cantly higher than that in retinas injected with AAV2/rh.43.
Conversely, AAV2/7, AAV2/8, and AAV2/9, which are the
FIG. 3. Strategy to assess levels of transgene expression following
AAV-mediated photoreceptor gene transfer. (A) To identify the AAV
serotype that results in the highest number of transduced photorecep-
tors, a bicistronic reporter was expressed in photoreceptors using the
photoreceptor-specific RHO promoter. The bicistronic reporter in-
cludes the sequence of NLSEGFP (see Results and Discussion for
details) followed by that of luciferase. NLSEGFP allows the qualitative
analysis of photoreceptor transduction by histology, while luciferase
allows us to quantify the transduction levels by a luminometric assay.
(B) To identify the promoter that results in the highest levels of
expression in photoreceptors, we generated AAV2/5 vectors encoding
the bicistronic reporter under the transcriptional control of various
promoters. IRES, internal ribosomal entry site sequence; BGHpA,
bovine growth hormone poly(A).
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most efficient photoreceptor-transducing vectors tested in this
study, belong to three different clades (AAV7, clade D; AAV8,
clade E; and AAV9, clade F), suggesting that overall capsid
sequence homologies are not predictive of AAV vector bio-
logical behavior and that few amino acid differences account
for significantly different biological activities (23). Interest-
ingly, AAV2/hu29 vectors show tropism similar to that of their
closer homolog, AAV2/2 (3, 7), from which they differ in that
AAV2/hu29 capsids lack the AAV2 heparin binding domain.
Since the heparin binding domain contributes to antigen-pre-
senting cell transduction and elicitation of cell-mediated im-
mune responses to AAV2 capsids (55), it is possible that
AAV2/hu29 capsid could avoid this. We also provide the first
evidence that photoreceptors derived from retinal stem cells
are amenable to genetic modification by AAV2/7, AAV2/8,
and AAV2/9. The use of retinal stem cells for cell therapy of
the retina is still very limited, primarily due to the high heter-
ogeneity of retinal stem cells cultured in vitro. The possibility
of genetically manipulating this cell population may be an
important step towards the employment of stem cells for ther-
apeutic purposes.
We believe that the remarkable results obtained with AAV-
FIG. 4. Levels of luciferase activity in the photoreceptors after subretinal injections of AAV. (A) Levels of luciferase activity 1 month after
subretinal injections of AAV2/5, AAV2/7, AAV2/8, AAV2/9, AAV2/rh.64R1, AAV2/rh.43, and AAV2/rh.29R vectors encoding the bicistronic
reporter from the RHO promoter. AAV2/5-CMV-LacZ was coinjected to normalize the variability due to subretinal administrations. The levels
of luciferase activity were normalized for -Gal expression levels. n, number of injected eyes. Differences from AAV2/5 expression levels that are
statistically significant are marked with an asterisk; P 0.05. (B) Fluorescence microscopy evaluation of EGFP expression 4 weeks after subretinal
injection of AAV2/5, AAV2/7, AAV2/8, or AAV2/9 vector encoding the bicistronic reporter. (C) Levels of luciferase activity 1 month after
subretinal injection of AAV2/5 vectors encoding the bicistronic reporter gene from the CMV, CBA, RHO, or RHOK promoter and AAV2/1-
CMV-LacZ. The levels of luciferase activity were normalized for -Gal expression levels. n, number of injected eyes.
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mediated gene transfer in RPE65-deficient small and large
animal models (and hopefully soon in humans) may not nec-
essarily apply to other retinal diseases. RPE65 animal models
and patients show severe impairment of retinal function with a
relatively preserved retinal structure, and the disease affects
RPE cells that can be relatively easily transduced by viral
vectors, thus representing an ideal setting for successful gene
replacement (32). For the more common and therapeutically
challenging photoreceptor diseases, vectors such as AAV2/7
and AAV2/8 may represent crucial tools to obtain therapeutic
efficacy.
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